Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19807169 | 0.83 | SMN1; SMN2 (0.38) | SMN1; SMN2TSHRLMNAALDH1A1KDM4E | |
| SCHEMBL20724739 | 0.81 | MAPK1 (0.48) | SMN1; SMN2TSHRLMNAALDH1A1KDM4E | |
| SCHEMBL19798441 | 0.73 | EPHX2 (0.49) | SMN1; SMN2TSHRLMNAALDH1A1KDM4E | |
| SCHEMBL13126725 | 0.73 | NPSR1 (0.30) | NPSR1 | |
| SCHEMBL19798442 | 0.72 | SMN1; SMN2 (0.44) | SMN1; SMN2TSHRLMNAALDH1A1KDM4E | |
| SCHEMBL19807174 | 0.72 | EPHX2 (0.39) | SMN1; SMN2TSHRLMNAALDH1A1KDM4E | |
| SCHEMBL19808494 | 0.71 | SMN1; SMN2 (0.43) | SMN1; SMN2TSHRLMNAALDH1A1KDM4E | |
| SCHEMBL19807175 | 0.70 | SMN1; SMN2 (0.36) | SMN1; SMN2TSHRLMNAALDH1A1KDM4E | |
| SCHEMBL9918346 | 0.70 | — | — | |
| SCHEMBL13126726 | 0.67 | CA2 (0.33) | LMNAALDH1A1CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | Shanghai De Novo Pharmatech Co., Ltd. (CN) | 2019-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10202388-B2 | Fused-ring compounds, pharmaceutical composition and uses thereof | IDO1, IDO2, TDO2 | SMN1; SMN2 3655/4885TSHR 2589/4885LMNA 4813/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.